4162 Share Price Performance
NT$72.00
-16.30 (-18.46%)
Price NT$72.00
Share PriceNT$72.00
PharmaEngine, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
4162 Community Narratives
There are no narratives available yet.
Recent 4162 News & Updates
PharmaEngine, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 11.35
- Gross Margin
- 98.05%
- Net Profit Margin
- 65.72%
- Debt/Equity Ratio
- 0%
PharmaEngine, Inc. Competitors
Snowflake Analysis
Outstanding track record with flawless balance sheet and pays a dividend.
2 Risks
2 Rewards
About 4162
- Founded
- 2002
- Employees
- 44
- CEO
- WebsiteView website
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Taiwanese Market Performance
- 7 Days: 3.2%
- 3 Months: 19.3%
- 1 Year: 18.5%
- Year to Date: 18.3%
Over the last 7 days, the market has risen 3.2%, driven by gains of 4.3% in the Information Technology sector. In contrast, the Healthcare sector is lagging, dropping 3.7%. In the last year, the market has climbed 19%. Looking forward, earnings are forecast to grow by 18% annually. Market details ›